Lexaria Bioscience Corp. (LEXX): R&D Expense
$8.24M
Year ended 2025-08-31
$4.00M
Trailing 12 months to 2026-05-31
+64.7%
3-year compound annual growth
+84.3%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-08-31 | $8.24M | +249.0% | 2025-11-28, From 2024-09-01 |
| 2024-08-31 | $2.36M | -35.6% | 2025-11-28, From 2023-09-01 |
| 2023-08-31 | $3.67M | +99.0% | 2024-11-26, From 2022-09-01 |
| 2022-08-31 | $1.84M | +45.9% | 2023-11-20, From 2021-09-01 |
| 2021-08-31 | $1.26M | +226.3% | 2022-11-28, From 2020-09-01 |
| 2020-08-31 | $387.1K | -30.3% | 2021-11-29, From 2019-09-01 |
| 2019-08-31 | $555.7K | +12.8% | 2020-10-15, From 2018-09-01 |
| 2018-08-31 | $492.9K | +809.6% | 2019-11-14, From 2017-09-01 |
| 2017-08-31 | $54.2K | +500.5% | 2018-11-14, From 2016-09-01 |
| 2016-08-31 | $9.0K | -93.8% | 2018-11-14, From 2015-09-01 |
| 2015-08-31 | $146.5K | n/a | 2016-11-29, From 2014-09-01 |
| 2014-08-31 | $0 | n/a | 2015-11-27, From 2013-09-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $8.24M | +249.0% |
| BioXcel Therapeutics, Inc. (BTAIQ) | 2025-12-31 | $30.25M | -0.6% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $1.91M | -86.8% |
| Onconetix, Inc. (ONCO) | 2024-12-31 | $154.4K | -92.1% |
| Vaccinex, Inc. (VCNX) | 2024-12-31 | $12.54M | -24.3% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $147.0K | +40.5% |
| Rallybio Corp (RLYB) | 2025-12-31 | $19.60M | -52.8% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $19.24M | -37.8% |
| Silence Therapeutics plc (SLN) | 2025-12-31 | $67.75M | -0.2% |
Compare LEXX, BTAIQ, HYPD, ONCO side by side · Screen every company in Pharmaceutical Preparations ↗